Day One Biopharmaceuticals (DAWN) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 1 Phase 2[2], 1 Phase 1[3].
Trial NCT05566795[5] evaluates Tovorafenib in Low-grade Glioma with a target enrollment of 400 participants.
No Form 4 insider filings for DAWN were recorded at the SEC in the past 30 days[6].